Cellectis

Cellectis is a biopharmaceutical company that develops and markets adoptive immunotherapy for cancer. Read more

Andre Choulika's photo - Chairman & CEO of Cellectis

Chairman & CEO

Andre Choulika

CEO Approval Rating

87/100

Founded:

1999

Status:

PublicIndependent CompanyNASDAQCLLS

CELLECTIS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

OncBioMune is Cellectis's top competitor. OncBioMune was founded in 2005 in Baton Rouge, Louisiana. OncBioMune competes in the Pharmaceuticals field. OncBioMune generates $73.5M less revenue than Cellectis.

Juno Therapeutics is perceived as one of Cellectis's biggest rivals. Juno Therapeutics's headquarters is in Seattle, Washington, and was founded in 2013. Like Cellectis, Juno Therapeutics also competes in the Biotechnology industry. Juno Therapeutics generates 143% of Cellectis's revenue.

Onxeo is one of Cellectis's top competitors. Onxeo is a Public company that was founded in Paris, Île-de-France in 1997. Like Cellectis, Onxeo also competes in the Biotechnology field. Onxeo has 64 fewer employees vs. Cellectis.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is CR Pharmaceutical a competitor of Cellectis?

Cellectis Quarterly and Annual Revenue

Coming soon for Cellectis!

Annual Revenue

$73.9M

Cellectis's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 3.1B.

Cellectis Acquisitions

No recent acquisitions found related to Cellectis

Cellectis Funding History

Since Cellectis was founded in 1999, it has participated in 3 rounds of funding. In total Cellectis has raised $271.9M. Cellectis' last funding round was on Mar 2015 for a total of $228.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Mar 2015
$228M
-
Equity
Mar 2014
$28.2M
Equity
Jul 2002
$15.7M

Since Cellectis was founded in 1999, it has participated in 3 rounds of funding. In total Cellectis has raised $271.9M. Cellectis' last funding round was on Mar 2015 for a total of $228.0M

Cellectis Investments

No recent investments found related to Cellectis

Cellectis News

June 10, 2021MarketScreener

Corporate Presentation - June 2021

(marketscreener.com) COMMITMENT TO A CURE Investor Presentation June 2021 cellectis.com FORWARD-LOOKI... See more »
June 2, 2021Markets Insider

Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meet... See more »
May 27, 2021MarketScreener

Shareholder's General Meeting - Broadcast Connection Instruction - June 1, 2021

(marketscreener.com) Broadcast connection instructions Cellectis' Shareholders Meeting June 1, 2021 2... See more »
May 11, 2021MarketScreener

and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

(marketscreener.com) May 11, 2021 - Paris - Cellectis S.A. , a clinical-stage biotechnological compan... See more »
April 27, 2021MarketScreener

Shareholders' General Meeting Notice - June 1, 2021

(marketscreener.com) CELLECTIS A French limited liability company with a share capital of € 2.272,740... See more »
April 9, 2021BioSpace

Cellectis Completes Sale of $47 million through its ATM program - Apr 09, 2021

Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies... See more »
March 30, 2021BioSpace

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

Cellectis S.A. (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS) (the "Company"), a clinical-stage biotechnolog... See more »

Cellectis Press Releases

September 7, 2020GlobalNewswire

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)... See more »
July 6, 2020GlobeNewswire

Cellectis Reports Clinical Hold Placed on MELANI-01 Study

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biop... See more »
July 6, 2020GlobalNewswire

To Fully Focus on Cellectis, Dr. Andr Choulika Retires From Calyxt's Board of Directors

Dr. Yves Ribeill, Member of Calyxt's Board of Directors since 2018, Appointed Chairman of the Board; ... See more »
May 12, 2020GlobalNewswire

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)... See more »
April 10, 2020StreetInsider

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)Â NEW YORK, April 10,... See more »
January 10, 2020centralcharts

Monthly Information on Share Capital and Company Voting Rights

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS): Listing market: Euronext Growth ISIN code: FR... See more »
October 7, 2019StreetInsider

Monthly Information on Share Capital and Company Voting Rights

(Article 223-16 of General Regulation of the French financial markets authority) PARIS--(BUSINESS WIR... See more »

Cellectis Videos

Social Media

Cellectis Headquarters

430 East 29th Street

New York, New York10016

1-347-752-4044

Driving Directions »

Trending Companies

Cellectis Summary

ABOUT

Overview

Cellectis is a biopharmaceutical company that develops and markets adoptive immunotherapy for cancer. Cellectis was founded in 1999. Cellectis' headquarters is located in New York, New York, USA 10016. It has raised 271.9M in 3 rounds. The latest roun...

CEO

Cellectis's Chairman & CEO, Andre Choulika, currently has an approval rating of 87%. Cellectis's primary competitors are OncBioMune, Juno Therapeutics & Onxeo.

Frequently Asked Questions about Cellectis

  1. When was Cellectis founded?

    Cellectis was founded in 1999
  2. Who is Cellectis's CEO?

    Cellectis's CEO is Andre Choulika
  3. How much revenue does Cellectis generate?

    Cellectis generates $73.9M in revenue
  4. How much funding does Cellectis have?

    Cellectis has historically raised $271.9M in funding
  1. Where is Cellectis's headquarters?

    Cellectis's headquarters is in New York New York, USA
  2. How many employees does Cellectis have?

    Cellectis has 89 employees
  3. What sector does Cellectis operate in?

    Cellectis is in Biotechnology
  4. Who are Cellectis's competitors?

    Cellectis's top competitors are OncBioMune, Juno Therapeutics, Onxeo